Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway

Knut Ketterer, Bo Kong, Dietwalt Frank, Nathalia A. Giese, Andrea Bauer, Jörg Hoheisel, Murray Korc, Jörg Kleeff, Christoph W. Michalski, Helmut Friess

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Neuromedin U (NmU) is a bioactive peptide, ubiquitously expressed in the gastrointestinal tract. Here, we analyzed the role of NmU in pancreatic ductal adenocarcinoma (PDAC) pathogenesis. NmU and NmU receptor-2 mRNA were significantly overexpressed in PDAC and in metastatic tissues. NmU and NmU receptor-2 were localized predominantly in cancer cells. NmU serum levels decreased after tumor resection. Although NmU exerted no effects on cancer cell proliferation, it induced c-Met and a trend towards increased invasiveness as well as an increased hepatocyte growth factor (HGF)-mediated scattering. Thus, NmU may be involved in the HGF-c-Met paracrine loop regulating cell migration, invasiveness and dissemination of PDAC.

Original languageEnglish (US)
Pages (from-to)72-81
Number of pages10
JournalCancer Letters
Volume277
Issue number1
DOIs
StatePublished - May 8 2009

Keywords

  • Metastasis
  • Neuromedin U
  • Neuromedin U receptor
  • Pancreatic cancer
  • c-Met

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway'. Together they form a unique fingerprint.

  • Cite this

    Ketterer, K., Kong, B., Frank, D., Giese, N. A., Bauer, A., Hoheisel, J., Korc, M., Kleeff, J., Michalski, C. W., & Friess, H. (2009). Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. Cancer Letters, 277(1), 72-81. https://doi.org/10.1016/j.canlet.2008.11.028